PVG Asset Management Corp purchased a new position in shares of Humana Inc (NYSE:HUM) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 915 shares of the insurance provider’s stock, valued at approximately $242,000.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in HUM. Cornerstone Advisors Inc. raised its position in Humana by 13.5% in the 2nd quarter. Cornerstone Advisors Inc. now owns 353 shares of the insurance provider’s stock valued at $94,000 after buying an additional 42 shares during the last quarter. Regentatlantic Capital LLC increased its position in shares of Humana by 0.4% during the 2nd quarter. Regentatlantic Capital LLC now owns 9,617 shares of the insurance provider’s stock worth $2,551,000 after purchasing an additional 42 shares during the last quarter. Cim Investment Mangement Inc. increased its position in shares of Humana by 4.3% during the 2nd quarter. Cim Investment Mangement Inc. now owns 1,125 shares of the insurance provider’s stock worth $298,000 after purchasing an additional 46 shares during the last quarter. Savant Capital LLC increased its position in shares of Humana by 2.5% during the 2nd quarter. Savant Capital LLC now owns 1,968 shares of the insurance provider’s stock worth $522,000 after purchasing an additional 48 shares during the last quarter. Finally, Greenleaf Trust increased its position in shares of Humana by 3.4% during the 2nd quarter. Greenleaf Trust now owns 1,652 shares of the insurance provider’s stock worth $438,000 after purchasing an additional 55 shares during the last quarter. 92.77% of the stock is currently owned by institutional investors.
NYSE HUM traded down $0.25 during midday trading on Friday, hitting $278.16. The company had a trading volume of 37,892 shares, compared to its average volume of 861,869. The company has a market capitalization of $36.98 billion, a PE ratio of 19.14, a P/E/G ratio of 1.18 and a beta of 0.84. The company has a current ratio of 1.75, a quick ratio of 1.75 and a debt-to-equity ratio of 0.37. The firm has a 50-day moving average price of $286.85 and a 200-day moving average price of $268.58. Humana Inc has a twelve month low of $225.65 and a twelve month high of $355.88.
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be issued a dividend of $0.55 per share. The ex-dividend date is Friday, September 27th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.79%. Humana’s dividend payout ratio (DPR) is currently 15.12%.
In other news, insider Brian P. Leclaire sold 7,239 shares of the business’s stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $289.70, for a total transaction of $2,097,138.30. Following the completion of the transaction, the insider now owns 12,994 shares of the company’s stock, valued at approximately $3,764,361.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.54% of the stock is currently owned by insiders.
Several research analysts have weighed in on the company. Cantor Fitzgerald raised Humana from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $300.00 to $345.00 in a research report on Monday, August 12th. JPMorgan Chase & Co. lifted their target price on Humana from $288.00 to $322.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st. Deutsche Bank assumed coverage on Humana in a research note on Thursday, September 12th. They set a “hold” rating and a $300.00 target price for the company. UBS Group lifted their target price on Humana from $266.00 to $317.00 and gave the stock a “neutral” rating in a research note on Thursday, August 1st. Finally, ValuEngine downgraded Humana from a “hold” rating to a “sell” rating in a research note on Wednesday, September 11th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $339.74.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Article: What is the significance of the death cross?
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.